- Report
- July 2022
- 100 Pages
Global
From €1912EUR$1,925USD£1,590GBP
€2732EUR$2,750USD£2,271GBP
- Report
- July 2022
- 53 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- July 2022
- 107 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- June 2022
- 67 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Clinical Trials
- June 2022
- 65 Pages
Global
From €1043EUR$1,050USD£867GBP
€1490EUR$1,500USD£1,239GBP
- Report
- March 2022
- 142 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- March 2022
- 166 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Drug Pipelines
- March 2022
- 83 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- February 2022
- 110 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- January 2022
- 92 Pages
Global
From €4833EUR$4,865USD£4,018GBP
€6904EUR$6,950USD£5,741GBP
- Report
- January 2022
- 60 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- January 2022
- 200 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- January 2022
- 60 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- January 2022
- 60 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- January 2022
- 60 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- January 2022
- 200 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- January 2022
- 60 Pages
Global
From €2747EUR$2,765USD£2,284GBP
€3924EUR$3,950USD£3,263GBP
- Report
- January 2022
- 200 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- January 2022
- 200 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
- Report
- January 2022
- 200 Pages
Global
From €5216EUR$5,250USD£4,336GBP
€7451EUR$7,500USD£6,195GBP
The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders.
Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists.
Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more